Company profile
Kura Oncology, Inc.
NASDAQ:KURABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Ziftomenib | approved | — | 5 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06655246 | phase1 | recruiting | 2025-03-27 | 2027-12-01 | Kura Oncology, Inc. | A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) |
| NCT05735184 | phase1 | recruiting | 2023-07-18 | 2030-04-01 | Kura Oncology, Inc. | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML |
| NCT04865159 | phase1 | terminated | 2021-05-06 | 2023-05-02 | Kura Oncology, Inc. | Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies |
| NCT04997902 | phase1_2 | completed | 2021-12-07 | 2025-08-29 | Kura Oncology, Inc. | Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) |
| NCT04067336 | phase1_2 | active_not_recruiting | 2019-09-12 | 2028-10-16 | Kura Oncology, Inc. | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 220305 | NDA | KURA ONCOLOGY INC | ||||
Loading… | ||||||